ZipBio Partners with MeiraGTx to Propel Gene Therapy Advancements

Exclusive Licensing Agreement between ZipBio and MeiraGTx

On February 3, 2026, ZipBio, known for its innovative AI-driven approach in protein therapeutics, announced a significant exclusive license agreement with MeiraGTx Holdings plc. This partnership aims to advance groundbreaking therapies for Geographic Atrophy by focusing on the complement pathway, which is crucial in a range of retinal diseases.

With this agreement, MeiraGTx acquires exclusive rights to ZipBio's pioneering therapies, marking an important step in the commercialization and development of these next-generation treatments. The collaboration showcases the strengths of both companies: MeiraGTx’s robust expertise in vector design, clinical development, and the in-house manufacturing of genetic medicines aligns perfectly with ZipBio’s cutting-edge technology in AI-designed protein therapeutics, powered by its proprietary COMPACT™ generative AI platform.

About the COMPACT™ Platform

The COMPACT™ platform is more than just a technological tool; it represents a paradigm shift in how protein therapeutics are conceived and developed. By enabling the design of compact, multifunctional, and logic-gated proteins, COMPACT™ allows ZipBio to target disease pathways that have traditionally eluded conventional biologics. This technology has catalyzed the development of a strong pipeline of therapies aimed at high-need areas, bolstered by strategic focus and insight into validated targets.

Roee Farber, MD, CEO of ZipBio, emphasizes the significance of this alliance by stating, "MeiraGTx's expertise in developing best-in-class genetic medicines in ophthalmology makes them the ideal partner to bring our next-generation AI-designed Geographic Atrophy therapies to patients with a significant unmet need." This sentiment underscores the commitment both companies have to address critical healthcare challenges through innovation.

Financial Overview of the Agreement

While specific financial details have not been disclosed, the licensing agreement encompasses both upfront sums and future milestone and royalty payments. This strategic partnership allows ZipBio to refine its focus on advancing its internal pipeline, particularly in areas such as immunology and cardiovascular disease.

The Future of AI in Drug Discovery

The collaboration between ZipBio and MeiraGTx is indicative of the increasing reliance on AI technologies in drug discovery processes. As the industry gravitates towards AI-enabled biologics, this partnership exemplifies the potential of leveraging artificial intelligence to create transformative therapies that can meet significant unmet medical needs.

About ZipBio and MeiraGTx

ZipBio is a biotechnology firm that designs advanced protein therapeutics using generative AI. By focusing on multi-specific and logic-gated biologics, the company aims to overcome past limitations in targeting complex disease pathways.

MeiraGTx, listed on Nasdaq under the ticker MGTX, is a leading entity in genetic medicine, with a diverse pipeline that includes late-stage clinical programs. These programs utilize innovative local delivery techniques to address various inherited and common diseases, including those affecting the eye and conditions like Parkinson's disease.

Conclusion

As ZipBio and MeiraGTx move forward with this partnership, the potential to revolutionize treatment options for patients suffering from Geographic Atrophy becomes increasingly tangible. The combination of their expertise and technologies could pave the way for breakthrough advancements in genetic medicine and protein therapeutics, ultimately improving countless lives in the process.